Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 13/20 | 0.83 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.83 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.63 |
| ▸ | HTR2B | P41595 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27332898 | 0.87 | OPRM1 (0.77) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL6045571 | 0.86 | OPRM1 (1.00) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL684578 | 0.86 | OPRM1 (0.77) | CHRM3SIGMAR1OPRM1DRD2 | |
| Hydrochloric Acid SCHEMBL29651340 | 0.85 | OPRM1 (0.97) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL7095304 | 0.85 | CHRM2 (0.69) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL31255945 | 0.85 | CHRM2 (1.00) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL15848501 | 0.85 | CHRM2 (0.72) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL2604437 | 0.85 | CHRM2 (0.81) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| Oxalic Acid SCHEMBL6045624 | 0.84 | OPRM1 (0.95) | CHRM2CHRM3SIGMAR1OPRM1MEN1 | |
| SCHEMBL9785706 | 0.84 | CHRM2 (0.67) | CHRM2CHRM3SIGMAR1OPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117664949-A | Detection method of surface-enhanced Raman nano particles and fentanyl substances | 深圳海关工业品检测技术中心 | 2024-03-08 | — | — | CN | claimed |
| CN-117664949-A | Detection method of surface-enhanced Raman nano particles and fentanyl substances | 深圳海关工业品检测技术中心 | 2024-03-08 | — | — | CN | disclosed |
| WO-2014116684-A1 | NON-PEPTIDIC NEUROPEPTIDE Y RECEPTOR MODULATORS | ROBERTS EDWARD (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | CHRM2 630/4885CHRM3 364/4885SIGMAR1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.